I'm going to speak about seed innovation because that's the area I'm most familiar with.
Globally, a number of countries are in a similar position to Canada, asking how these new products should be regulated, and if these products will fall under existing legislation for biotechnology. A number of countries have been able to come forward with clarity for innovators. We see that Australia, the U.S., and a number of countries in Latin America have been able to produce guidance so that innovators in those jurisdictions understand whether the products they're developing will be regulated or not. They have a sense of the types of requirements they'll need to meet, and how long that process will take.
There are no products of gene editing currently commercialized, but we would anticipate that the first products will be in the United States. These are products developed by both small start-up companies and larger multinational companies.